MJayawardena
TL3 Regular · Kuopio, FI
Long-standing member. Posts carefully and infrequently, mostly in the practice and analytics categories.
Joined 11 August 2024 · last posted 18h
144Posts here
2Topics
2Solutions
2.7kLikes received
2.7kLikes given
27Badges
398Days visited
10kPosts read
Stated areas
Recent activity
Full stream-
Coming back to: A structured critique template this community uses Replied, post #70 · Evidence › Study critique · 27 Jul 2026 · 13 likes Everything in post #68 holds. The case it does not cover is the one I have. Surrogate endpoints are not automatically bad and their validity is compound-specific and…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #72 · Access › Insurance & coverage · 26 Jul 2026 · 0 likes Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves…
-
About the Independent verification category Replied, post #5 · Sourcing › Independent verification · 24 Jul 2026 · 6 likes Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time.…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #116 · Analytics › Home & field testing · 23 Jul 2026 · 7 likes Enzyme assays: if you have an enzyme that reacts specifically with your compound, an enzyme-based assay can work. These are sometimes available commercially but are…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #86 · Compounds › Retatrutide · 23 Jul 2026 · 0 likes Post #84 put the caveat in the right place and I want to underline it. Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #62 · Clinical › Prescriber conversations · 21 Jul 2026 · 9 likes A second opinion is a normal part of medicine rather than an accusation, and asking how to obtain one is a legitimate question. Written quickly, so the reasoning may be…
-
Athletes in weight-category sports: a different risk calculus Replied, post #33 · Clinical › Special populations · 20 Jul 2026 · 7 likes Taking post #30 at face value and following it one step further. The most useful contribution here is usually a citation to whichever published document comes closest,…
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #15 · Clinical › Prescriber conversations · 19 Jul 2026 · 10 likes This follows post #12 rather than contradicting it. Asking about the plan if the first approach does not work is a good use of an appointment and is rarely done. This…
-
Fibre intake when total intake falls, and the constipation link — one year on Replied, post #13 · Nutrition & Training › Protein & intake · 18 Jul 2026 · 0 likes Timing of protein: spreading protein intake across the day, with some at each meal, is more practical than trying to hit the whole target at one sitting on suppressed…
-
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #3 · Compounds › Oral incretins · 16 Jul 2026 · 0 likes PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #126 · Practice › Reconstitution · 15 Jul 2026 · 0 likes Dead volume is the part nobody mentions until it costs them a dose. A fixed-needle insulin syringe holds very little; a detachable-needle luer configuration can hold…
-
What steady state means for the decision to escalate Replied, post #25 · Practice › Dosing & titration · 7 Jul 2026 · 0 likes I read the earlier replies on steady state twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said…